Table 2.

Post-COVID-19 symptoms at week 4

Symptom	All	BNT162b2	Unvaccinated	P valuea
General symptoms
Tiredness or fatigue	136 (41.2%)	71 (40.6%)	65 (41.9%)	0.802
Symptoms that get worse after physical or mental ctivities	50 (15.2%)	18 (10.3%)	32 (20.6%)	0.009
Fever	1 (0.3%)	0 (0.0%)	1 (0.7%)	0.470
General pain/discomfort	50 (15.2%)	20 (11.4%)	30 (19.4%)	0.045
Respiratory and cardiac
Difficulty breathing or shortness of breath	58 (17.6%)	26 (14.9%)	32 (20.6%)	0.168
Cough	86 (26.1%)	40 (22.9%)	46 (29.7%)	0.159
Chest or stomach pain	32 (9.7%)	14 (8.0%)	18 (11.6%)	0.268
Fast-beating or pounding heart (also known as heart palpitations)	38 (11.5%)	17 (9.7%)	21 (13.5%)	0.276
Neurologic
Change in smell or taste	51 (15.5%)	19 (10.9%)	32 (20.6%)	0.014
Headache	67 (20.3%)	28 (16.0%)	39 (25.2%)	0.039
Dizziness on standing (lightheadedness)	45 (13.6%)	20 (11.4%)	25 (16.1%)	0.214
Difficulty thinking or concentrating (sometimes referred to as “brain fog”)	86 (26.1%)	43 (24.6%)	43 (27.7%)	0.513
Pins-and-needles feeling	24 (7.3%)	10 (5.7%)	14 (9.0%)	0.247
Sleep problems	81 (24.5%)	35 (20.0%)	46 (29.7%)	0.042
Mood changes	36 (10.9%)	13 (7.4%)	23 (14.8%)	0.031
Memory loss	38 (11.5%)	11 (6.3%)	27 (17.4%)	0.002
Other
Diarrhea	23 (7.0%)	6 (3.4%)	17 (11.0%)	0.007
Joint or muscle pain	67 (20.3%)	29 (16.6%)	38 (24.5%)	0.073
Rash	11 (3.3%)	3 (1.7%)	8 (5.2%)	0.082
Changes in period cycles	28 (11.5%)	12 (9.4%)	16 (13.8%)	0.280
Number of post-COVID-19 symptoms, mean (SD)	3.1 (3.6)	2.5 (3.0)	3.7 (4.1)	0.002
0	100 (30.3%)	54 (30.9%)	46 (29.7%)	0.001
1–2	100 (30.3%)	59 (33.7%)	41 (26.5%)
3–5	61 (18.5%)	40 (22.9%)	21 (13.5%)
6–8	32 (9.7%)	9 (5.1%)	23 (14.8%)
≥ 9	37 (11.2%)	13 (7.4%)	24 (15.5%)

^aP-values of t-test for number of symptoms, chi-square or Fisher’s exact tests when any one cell has an expected frequency less than 5 for individual symptoms and number of symptom category comparing the BNT162b2 cohort and the unvaccinated cohort